GlassScriptPhysician profile
Xiumei Zhao
NPI 1619554938
$1,289.04
in general payments reported to CMS, 2019-2025
20 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $269 · 2024: $660 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.05 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $301.90 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Esperion Therapeutics, INC. | $142.96 | 2023-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $112.89 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $97.83 | 2024 | Arcalyst |
| Amgen INC. | $86.96 | 2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $86.37 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $84.28 | 2024-2025 | Camzyos, Eliquis |
| Inspire Medical Systems, INC. | $72.74 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.16 | 2023-2025 | Jardiance |
| Pfizer INC. | $37.66 | 2023-2024 | |
| Novo Nordisk INC | $37.26 | 2025 | Wegovy |
| Irhythm Technologies, INC. | $28.01 | 2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $22.03 | 2024 | Watchman Access System |
| Bridgebio Pharma, INC. | $21.65 | 2025 | Attruby |
| Philips North America LLC | $21.20 | 2024 | (Ck4) Mcot |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.57 | 2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $19.08 | 2024 | Xarelto |
| Kiniksa Pharmaceuticals, LTD. | $17.65 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $16.82 | 2024 | Farxiga |
| Chiesi USA, INC. | $16.02 | 2023 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiumei Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.